EUPRAXIA PHARMACEUTICALS INC.

Insiders Eupraxia Pharmaceuticals Inc.

Equities

EPRX

CA29842P1053

Market Closed - Toronto S.E. Other stock markets 03:59:59 2024-06-14 pm EDT			5-day change	1st Jan Change
3.65 ^CAD	0.00%		-2.14%	-32.03%

Jun. 05	Eupraxia Pharmaceuticals Inc. Brief: Says To Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024	MT
May. 23	Eupraxia Pharmaceuticals Expanding RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	MT

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Eupraxia Pharmaceuticals Forms Gastrointestinal Clinical Advisory Board	May. 02	MT
Eupraxia Pharmaceuticals Inc. Appoints Mark Kowalski as Chief Medical Officer	23-05-18	CI
Eupraxia Pharmaceuticals Inc. Brief: Appointing Mark Kowalski, MD, PhD, as Company's Chief Medical Officer, effective May 18, 2023	23-05-18	MT
Eupraxia Pharmaceuticals Inc. Appoints Industry Veteran, Paul Brennan, As Chief Business Officer	22-11-01	MT
Eupraxia Pharmaceuticals Appoints Paul Brennan to Chief Business Officer	22-11-01	CI
Eupraxia Pharmaceuticals Inc. Elects Richard M. Glickman to Board of Directors	21-12-03	CI
Eupraxia Pharmaceuticals : Names New CFO	21-05-03	MT
Eupraxia Pharmaceuticals Inc. Appoints Bruce Cousins as New President, Effective May 3, 2021	21-05-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer